fail to respond to IM treatment and their disease continues to progress, indicating resistance to IM therapy. 3, 4 The mechanism underlying resistance to IM is a complex network involving multiple cellular and molecular mechanisms.
Mutations of BCR-ABL do not account for all cases of resistance to IM therapy. Recently, attention has been drawn to the BM microenvironment, which plays an important role in the differentiation, migration, proliferation, survival, and drug resistance of leukemia cells. 5, 6 The chemoprotective effect of the BM microenvironment has been shown using in vitro CML cellular models under IM treatment. [6] [7] [8] [9] [10] [11] For example, cytokines within the BM microenvironment, such as interleukin (IL)-3, IL-7, granulocyte-macrophage colony-stimulating factor, and C-X-C motif chemokine 12, can protect CML cells from IM-induced apoptosis and promote CML cell survival. [7] [8] [9] [10] [11] However, it remains unknown whether there are other soluble factors that are chemoprotective for CML cells under IM treatment.
Cysteine-rich protein 61 (Cyr61/CCN1), a member of the CCN protein family, is an extracellular matrix-associated protein that plays essential roles in cellular proliferation, survival, adhesion, migration, and differentiation. 12 As a secreted protein, Cyr61 plays unique roles in different tumor types. For example, in breast cancer, 13, 14 prostate cancer, 15, 16 and pancreatic carcinoma, 17 Cyr61 functions as an oncogenic factor. In contrast, Cyr61 suppresses tumor growth in non-small cell lung cancer, 18, 19 endometrial adenocarcinoma, 20 and melanoma. 21 Interestingly, more and more studies have shown that Cyr61 is linked to chemotherapy resistance. Specifically, Cyr61
protects tumor cells from chemo-induced apoptosis and increases cell survival in solid tumors, such as in breast cancer, 22, 23 ovarian cancer, 24 pancreatic adenocarcinoma, 25 and renal cell carcinoma. 26 Recent studies have indicated that Cyr61 is involved in stroma-induced chemoresistance in AML. 27 In our previous research, we observed that the levels of Cyr61 were increased in the plasma and BM of patients with acute lymphoblastic leukemia (ALL), and elevated Cyr61 promoted cell survival. 28 However, the level of Cyr61 in patients with CML and its involvement in IM-induced CML cellular apoptosis have not been reported.
In the present study, we examined Cyr61 levels in patients with CML and the function of Cyr61 in modulating the sensitivity of CML K562 cells to IM. We found that Cyr61 levels were elevated in the plasma and BM of patients with CML. Furthermore, we observed that Cyr61 effectively reduced IM-induced apoptosis by the NF-κB/B-cell lymphoma 2 (Bcl-2) pathway. To our knowledge, this study is the first to show the expression and role of Cyr61 in patients with CML, suggesting that targeting Cyr61 or its effector pathways could improve the clinical response in patients with CML.
| MATERIAL S AND ME THODS

| Patients and specimens
Chronic myelogenous leukemia samples were obtained from
Fujian Medical University Union Hospital, Fuzhou, China. The BM supernatant (n = 33) and plasma (n = 36) samples were collected from newly diagnosed patients who had not received treatment. Normal BM (n = 11) and normal plasma (n = 66) samples from age-matched healthy transplant donors were included as controls. 
| Enzyme-linked immunosorbent assay
Concentrations of Cyr61 in the plasma and BM from CML patients were quantitated using the human Cyr61 ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Three internal quality control serum samples or BM supernatants were tested in each assay to assess interassay precision.
| Cysteine-rich protein 61 knockdown
Lentivirus-based shRNAs, scramble (shNC) or against Cyr61 (shCyr61), were purchased from Shanghai GeneChem Co., Ltd. The target sequence of shCyr61 was 5′-CAACGAGGACTGCAGCAAA-3′.
The viral particles were prepared with a standard method according to the manufacturer's instructions (GeneChem Co., Ltd, Shanghai, China). Viruses were collected at 72 hours post-transfection to infect K562 cells. Transduction efficiency of K562 cells was confirmed to be >97% before selection with 0.5 μg/mL puromycin (Sigma-Aldrich, St Louis, MO, USA) for 5 days. The knockdown efficiency of Cyr61 was evaluated by western blotting. 
| Apoptosis assay
| Real-time PCR analysis
Total RNA was extracted from specimens using a TriPure Isolation Reagent 
| Western blot analysis
Experimental cells were collected. In order to block secretion of Cyr61, K562, Jurkat, and Nalm-6 cells were treated with Brefeldin A (BD Biosciences, 5 μL/mL culture medium) and monensin (BD Biosciences, 2.5 μL/mL culture medium) for 5 hours. After washing with ice-cold PBS, cells were added to the RIPA lysis buffer for 20 minutes. Protein immunoblotting was done as described previously. 28 The following antibodies were used in this study: antihuman cyr61 monoclonal antibody (093G9) was kindly gifted by Dr Ningli Li 
| Mice and tumor xenografts
For tumor xenografts, K562-shCyr61 or K562-shNC cells were cultured in RPMI 1640 medium with 10% FBS in a 37°C incubator supplied with 5% CO 2 . Before inoculation, the cells were concentrated by centrifugation and suspension in serum-free medium to 
| Statistical analysis
Results are presented as mean ± standard error of the mean (SEM) unless indicated otherwise. Statistical analyses were carried out using SPSS software version 13.0 (SPSS Inc.). Significance of differences between groups was assessed by Student's t test for single comparisons or by analysis of variance for multi-group comparisons.
A value of P < 0.05 was considered to indicate statistical significance. Taken together, these data indicated that Cyr61 is upregulated in CML, suggesting an essential role for Cyr61 in the pathogenesis of CML.
| RE SULTS
| Presence of Cyr61 effectively reduces the sensitivity of CML cells to IM
Previous studies have shown that Cyr61 plays an important role in resistance to chemotherapeutic drug-induced apoptosis in human breast cancer, 22, 23 ovarian cancer, 24 pancreatic adenocarcinoma, 25 and renal cell carcinoma. 26 Recently, Long et al 27 
| Cysteine-rich protein 61 activates Bcl-2 transcription in CML cells
As Bcl-2 family molecules are important regulators of cellular apoptosis, we examined Bcl-2, Bcl-xL, XIAP, and Survivin transcription in Cyr61-treated K562 cells by qRT-PCR. As shown in Figure 3A , Bcl-2 mRNA was significantly increased in Cyr61-treated K562 cells, whereas the expression of Bcl-xL, XIAP, and
Survivin mRNA was not affected. Simultaneously, shRNA was used to knock down Cyr61 expression in K562 cells. As expected, we observed that Bcl-2 transcription was markedly decreased in Cyr61-knockdown K562 cells ( Figure 3B ). In addition, Bcl-2 protein expression was significantly increased in Cyr61-treated K562 cells and decreased in Cyr61-knockdown K562 cells ( Figure 3A,B) .
Last, a Bcl-2 inhibitor (ABT199) was used to block the function of Bcl-2 in Cyr61-treated K562 cells. We found that blocking Bcl-2 function restored K562 cell apoptosis induced by IM ( Figure 3C ).
Together, these results suggested that the IM-induced apoptosis of K562 cells is regulated by Cyr61, possibly through the upregulation of Bcl-2.
| Cysteine-rich protein 61 inhibits IM-induced apoptosis through the NF-κB signaling pathway
Previous studies have shown that NF-κB, 22 , and K562 cells were detected by western blotting. Band intensity of Cyr61 was quantified by densitometry and normalized to GAPDH. E, Concentration of Cyr61 in the culture supernatant of Jurkat, Nalm-6, and K562 cells was detected by ELISA. Data represent mean ± SEM of at least 3 independent experiments. *P < 0.05, **P < 0.01 namely, PDTC (an inhibitor of NF-κB activation), LY294002 (an inhibitor of the PI3K/AKT pathway), and PD98059 (an inhibitor of ERK1/2). As shown in Figure 4A , compared with Cyr61 alone, IM-induced CML cellular apoptosis was markedly increased in the presence of Cyr61 together with the NF-κB inhibitor, whereas inhibition of AKT and ERK1/2 activity had no effect on apoptosis. In addition, the AKT inhibitor alone, ERK1/2 inhibitor alone, or NF-κB inhibitor alone had no effect on CML cellular apoptosis (data not shown). Further analysis showed that Cyr61 treatment led to a dramatic increase in the phosphorylation of the NF-κB p65 subunit in IM-treated K562 cells ( Figure 4B ). Next, we treated the cells with PDTC to determine whether NF-κB is associated with the Cyr61-mediated regulation of Bcl-2. Our results indicated that treatment with PDTC blocked the activation of Bcl-2 transcription by Cyr61 in IM-treated K562 cells ( Figure 4C ).
To further examine the autocrine role of Cyr61 in the regulation of NF-κB phosphorylation and Bcl-2 expression in K562 cells, we used specific siRNA to knock down Cyr61 expression in K562 cells. The results showed that NF-κB phosphorylation and Bcl-2 expression were markedly reduced in Cyr61-knockdown K562 cells ( Figure 4D ). In conclusion, our data showed that IM-induced CML cellular apoptosis is negatively regulated by Cyr61, likely through the NF-κB pathway by upregulating Bcl-2. 
| Inhibition of Cyr61 restores the chemosensitivity of CML cells to IM in vivo
| D ISCUSS I ON
Imatinib mesylate is an effective treatment for CML as a result of its highly selective binding to the ATP-binding site of BCR-ABL protein and inhibition of BCR-ABL activation. Despite this, not all patients respond to the therapy, indicating that some factors potentially interfere with IM treatment in certain groups of patients.
In the present study, we first showed that Cyr61 levels were increased in the plasma and BM of patients with CML. Furthermore, we provided key evidence showing that the increased levels of Cyr61 in BM protected CML cells from IM-induced apoptosis. These findings suggested that Cyr61 may interfere with IM treatment.
As mentioned earlier, Cyr61 overexpression promotes the growth of solid tumors. [13] [14] [15] [16] [17] Our recent study showed that Cyr61 levels are increased in the plasma and BM of patients with ALL, and elevated Cyr61 levels promote cell survival. 28 In the present study, we discovered that Cyr61 levels were also upregulated in the plasma and BM of patients with CML, suggesting that Cyr61 may play an important role in the pathogenesis of CML.
Previous studies have shown that Cyr61 decreases the apoptosis induced by anticancer drugs in breast cancer cells, 22, 23 ovarian carcinoma cells, 24 renal cell carcinoma, 26 and AML, 27 suggesting that Cyr61 is linked to chemotherapy resistance in tumors.
However, whether Cyr61 is involved in chemoresistance in CML has not been reported. In this work, we explored the function of with IM treatment. Our previous findings also showed that blocking Cyr61 activity with specific antibodies ameliorates the severity of rheumatoid arthritis 33, 34 and psoriasis. 35 In addition, it has been reported that a secondary structure, called the G-quadruplex (G4) structure, can form on the 3′-untranslated region of Cyr61 mRNA, potentially modulating its translation. [36] [37] [38] [39] For example, therapeutic strategies using either G4 stabilizing small molecules or a nucleic acid clamp approach could possibly be used to modulate the stability of this mRNA G4 structure, and thus the translation of Cyr61. [40] [41] [42] [43] In conclusion, Cyr61 plays important roles in the survival of CML cells and could potentially serve as a molecular target for the treatment of CML.
It is well known that the regulation of cellular apoptosis is determined by the balance of anti-apoptotic and pro-apoptotic factors of Bcl-2 family proteins. 44 We evaluated the effect of Cyr61 on the expression of Bcl-2, Bcl-xL, XIAP, and Survivin.
Our findings showed that Cyr61 upregulated Bcl-2 expression Considering the complexity of the BM microenvironment with a variety of cytokines, chemokines, and other growth factors, [6] [7] [8] [9] [10] [11] 46 in vitro studies seem to be insufficient to elucidate the role that 
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